Skip to content
The Policy VaultThe Policy Vault

Inrebic (fedratinib) — United Healthcare

intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis

Initial criteria

  • Diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis

Reauthorization criteria

  • Documentation that patient has evidence of symptom improvement or reduction in spleen volume while on Inrebic

Approval duration

12 months